返回 Agenda
Session Chair(s)
Gregory Levin, PHD
Associate Director for Statistical Science and Policy, OB, OTS, CDER
FDA, United States
Keaven Anderson, PHD
Scientific AVP, Methodology Research
Merck & Co., Inc., , United States
Speaker(s)
Issues in Qualifying Biomarkers As Surrogate Endpoints
Victor DeGruttola, PHD
Harvard School of Public Health, United States
Henry Pickering Walcott Prof of Biostatistics & Chair, Dept of Biostatistics
Choosing Outcomes in Clinical Research: Biomarkers and Other Indirect Outcome Measures
John H. Powers, MD, FACP
George Washington University School of Medicine, United States
Professor of Clinical Medicine
Biomarkers and Longitudinal Modeling in I-SPY 2 and I-SPY 3
Donald A Berry, PHD
M.D. Anderson Cancer Center, United States
Professor, Department of Biostatistics
Discussant
Sue-Jane Wang, PHD, MA, MS
FDA, United States
Mathematician Statistician